Abstract:K-Ras is the most commonly mutated oncogene in human cancer, yet direct small-molecule targeting of K-Ras mutants has been mostly unsuccessful until recently. The discovery of an allosteric pocket under Switch-II with covalent cysteine-crosslinking molecules has allowed for the development of targeted therapies that selectively engage the highly reactive acquired cysteine in the K-Ras(G12C) mutation without affecting the wild-type protein. Sotorasib and adagrasib, two advanced Switch-II Pocket inhibitors, have received FDA approval to treat K-Ras(G12C)-driven non-small cell lung cancer. However, the most frequent K-Ras mutation G12D particularly prevalent in pancreatic ductal adenocarcinoma has remained untargetable with covalent drugs due to the poor nucleophilicity of the somatic aspartate residue. Here we present a set of malolactone-based electrophiles which exploit ring strain to crosslink K-Ras(G12D) at the mutant aspartate to form stable covalent complexes. Structural insights from x-ray crystallography and exploitation of the stereoelectronic requirements for attack of the electrophile allowed development of a substituted malolactone which resisted attack by aqueous buffer but rapidly crosslink with the aspartate-12 of K-Ras in both GDP- and GTP-state. The signaling-competent GTP-state targeting allowed effective suppression of downstream signaling and proliferation of cancer cells harboring K-Ras(G12D) mutation, and tumor growth of cell line-derive xenograft in mice. Our results demonstrate the rational design of covalent inhibitors to target a non-catalytic carboxylic acid side chain in K-Ras(G12D) which has resisted traditional drug discovery efforts. ### Competing Interest Statement K.M.S., Z.Z., and Q.Z. are inventors on patents related to covalent K-Ras(G12D) inhibitors reported here. K.M.S. is an inventor on patents owned by University of California San Francisco covering KRAS targeting small molecules licensed to Araxes, Erasca and Novartis. K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Novartis, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Mitokinin, Type6 Therapeutics, Nested Therapeutics, Vevo, Wellspring Biosciences (Araxes Pharma), Ikena, Initial Therapeutics and BioTheryX.

A Novel Strategy for Identifying Non-covalent KRas Inhibitors

KRAS is Vulnerable to Reversible Switch-Ii Pocket Engagement in Cells

Modeling receptor flexibility in the structure-based design of KRAS G12C inhibitors

Modeling receptor flexibility in the structure-based design of KRASG12C inhibitors

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects

Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D

Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations

Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody

Drugging K-RasG12C through covalent inhibitors: Mission possible?

Research Based on the Structure of KRAS Protein

Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers

Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Strain-release alkylation of Asp12 enables mutant selective GTP-state targeting of K-Ras(G12D)

Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.

Research Progress on Small Molecule Inhibitors Targeting KRAS G12C with Acrylamide Structure and the Strategies for Solving KRAS Inhibitor Resistance

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy

Computer-aided drug design of some KRAS G12C inhibitors: Targeting the covalent and allosteric binding site for cancer therapy